159 related articles for article (PubMed ID: 32269210)
1. Rituximab Use and Hypogammaglobulinemia.
Alhassan E; Johnson J; Nakity R; Shah HZ
Am J Case Rep; 2020 Apr; 21():e920681. PubMed ID: 32269210
[TBL] [Abstract][Full Text] [Related]
2. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
Besada E
BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
[TBL] [Abstract][Full Text] [Related]
3. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
4. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
Kridin K; Ahmed AR
Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
[TBL] [Abstract][Full Text] [Related]
5. [Psoriatic arthritis during rituximab treatment of granulomatosis with polyangiitis: a new paradoxical side effect?].
Aussy A; Girszyn N; Vandhuick T; Marie I; Vittecoq O; Lévesque H; Benhamou Y
Rev Med Interne; 2015 Jul; 36(7):491-4. PubMed ID: 25554400
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kawakami A
Intern Med; 2018 Aug; 57(15):2247-2250. PubMed ID: 29526948
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
9. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.
Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J
Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
11. Rituximab induction without maintenance for granulomatosis with polyangiitis and dialysis - Case report and literature review.
Kolitz T; Tanay A; Biro A; Zandman-Goddard G
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):535-540. PubMed ID: 31174822
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
13. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases.
Dalkilic E; Alkis N; Kamali S
Mod Rheumatol; 2012 Jun; 22(3):463-6. PubMed ID: 21847703
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report.
Ooka S; Maeda A; Ito H; Omata M; Yamada H; Ozaki S
Mod Rheumatol; 2009; 19(1):80-3. PubMed ID: 18806927
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment of a patient with refractory Wegener's granulomatosis by rituximab].
Minami R; Miyamura T; Watanabe H; Takahama S; Yamamoto M; Suematsu E
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Apr; 30(2):133-8. PubMed ID: 17473516
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
[TBL] [Abstract][Full Text] [Related]
18. [Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis].
de Groot K; Aries PM; Haubitz M; Hellmich B; Lamprecht P; Thiel J
Dtsch Med Wochenschr; 2020 Jan; 145(1):40-46. PubMed ID: 31914468
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
